Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 8356

Next Previous
Search
Drug Profile

SP 8356

Alternative Names: SP-8356

Latest Information Update: 28 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shin Poong Pharmaceutical
  • Class Terpenes; Vascular disorder therapies
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atherosclerosis; Stroke

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Atherosclerosis(In volunteers) in United Kingdom (PO, Powder)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Stroke(In volunteers) in United Kingdom (PO, Powder)
  • 10 Oct 2022 Shin Poong Pharmaceutical terminates a phase-I clinical trials in Atherosclerosis (In volunteers) in United Kingdom due to the low exposures and definitive safety conclusions could not be made for the targeted exposure levels in the future (PO) (NCT05574166)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top